Cannabis Countdown: Top 10 Marijuana And Psychedelic Stock News Stories Of The Week

Welcome to the Cannabis Countdown. In This Week’s Edition, We Recap and Countdown the Top 10 Marijuana and Psychedelic Stock News Stories for the Week of December 7th – 13th, 2020.

Without further ado, let’s get started.

* Yahoo Finance readers, please click here to view the full article.

10. Psychedelic Stocks Go Ballistic as Shroom Boom Reignites + Top Gainers of 2020

Since the Compass Pathways NASDAQ IPO in Mid-September, Psychedelic Stocks Have Gone on an Absolute Tear Racking Up Eye-Popping Gains in the Process

As we approach the end of 2020, let’s take a look back and highlight the Psychedelics industry’s most important regulatory developments as well as the sector’s top-performing Psychedelic Stocks.

READ FULL TOP PSYCHEDELIC STOCKS ARTICLE

9. Red White & Bloom Announce Michigan Launch of High Times Branded Cannabis Products

Thanks to the State’s Rapid Growth, Michigan is Now the 5th Highest-Grossing State, Recently Surpassing Nevada and on Track to Reach Sales of $1 Billion

Red White & Bloom RWBYF announced the phase one roll-out of the company’s High Times branded cannabis products in Michigan. The launch of RWB’s new exclusive product lineup will be done via existing licensed operators throughout Michigan, with the initial lineup consisting of Cannabis flower, pre-rolls, vapes and edible gummies.

READ FULL RED WHITE & BLOOM ARTICLE

8. Canopy Growth Shutters Facilities Across Country, Impacting 220 Employees

The Cuts to Production Are Being Undertaken as the Company Looks to “Streamline Operations and Further Improve Margins

The outlook for Cannabis operators in Canada is appearing bleak, with the announcement by Canopy Growth CGC that it is shuttering numerous facilities across the country, along with its outdoor grow operations. In total, 220 employees are said to be impacted by the closures.

READ FULL CANOPY GROWTH ARTICLE

7. Numinus Wellness Commends Health Canada for its Intent to Make MDMA and Psilocybin Treatment Available Through the Special Access Programme

The First-of-its-Kind Policy Amendment Will Allow Legal Access to Evidence-Based Treatments to Those in Need Before Formal Drug Approval

Numinus Wellness LKYSD announced that the company commends Health Canada‘s leadership for its intention to revise the Special Access Programme (SAP) to permit access to MDMA and Psilocybin-assisted psychotherapy. The intended SAP revision, announced today, will positively affect the lives of the many Canadians experiencing mental health conditions who have not responded to existing therapies.

READ FULL NUMINUS ARTICLE

6. 7 Cannabis Stocks That Should Be Profitable in 2021

At Long Last, North American Pot Stocks Are Going to Deliver the Green

After (pardon the pun) weeding through dozens of Marijuana Stocks, I found seven that Wall Street forecasts will be profitable in the upcoming year. Here they are, in no particular order: Green Thumb GTBIF, Trulieve TCNNF, Curaleaf CURLF, Cresco Labs CRLBF, Innovative Industrial Properties IIPR, Planet 13 PLNHF and Columbia Care CCHWF.

READ FULL PROFITABLE CANNABIS STOCKS ARTICLE

5. Psychedelics Could Transform the $2.5 Trillion Mental Health Market

Psychedelics Could Soon Disrupt the $2.5 trillion Mental Health Market as Clinical Studies Begin to Uncover its Benefits in Treating OCD, PTSD, Opioid Addiction, Alcoholism, Eating Disorders, Depression and Anxiety

As the Psychedelics story gains momentum, some of the top Psychedelic Stocks to watch include Cybin Inc. CYBN, MindMed MMEDF, Compass Pathways CMPS, Numinus Wellness LKYSD, and Havn Life Sciences HAVN.

READ FULL PSYCHEDELICS MARKET ARTICLE

4. There’s Lots More Upside to Trulieve Cannabis, Says Beacon Securities

Florida-Based Trulieve, the First and the Largest Fully-Licensed Cannabis Company in the Sunshine State With 68 Dispensaries, Announced on Monday the Opening of a New in Clermont, Near Orlando

Beacon Securities analyst Russell Stanley likes the trajectory for Trulieve TCNNF, which just opened its 73rd dispensary in the U.S. In an update to clients, Stanley reiterated his “Buy” recommendation and one-year target of C$64.00, saying the company’s Florida retail buildout has surpassed expectations in 2020.

READ FULL TRULIEVE ARTICLE

3. Psychedelic Stocks Start the Week Off at All-Time Highs

Psychedelic Firms Have Been Stepping up Their Game, and Investors Have Taken Notice

Since announcing it was working in conjunction with Health Canada on revisions to the Special Access Program (SAP) that would permit greater access to controlled substances such as MDMA and Psilocybin, the stock price at Numinus Wellness LKYSD has soared. Shares of the majority of Psychedelic Stocks, including Revive Therapeutics RVVTF, MindMed MMEDF and Havn Life Sciences HAVN have also skyrocketed in response to the Health Canada news.

READ FULL PSYCHEDELIC STOCKS ARTICLE

2. 3 U.S. Cannabis Stocks Gearing Up for Growth; Cantor Says ‘Buy’

Cantor Analyst Pablo Zuanic Recently Met With Several Cannabis Industry Execs and Came Back With a Few Takeaways

Prepping for the possible regulatory changes in the U.S., Zuanic has also been reviewing several Cannabis Stocks operating in the American market. Using the TipRanks database, we’ve pulled up the stats on the following three Pot Stocks, which show the classic ‘growth stock’ profile: plenty of upside potential, recent strong share appreciation, and a “Strong Buy” rating from the analyst consensus: Curaleaf CURLF, Green Thumb GTBIF and Cresco Labs CRLBF.

READ FULL U.S. POT STOCKS ARTICLE

1. Psychedelics Replace Pot as the New Favourite Edgy Investment

Cannabis is Only on the Cusp of Many Investors’ Comfort Zones, But the Family Offices and High-Net-Worth Individuals Hungry for Early-Stage, Edgy Investments Have Already Moved on to Psychedelics

As with Marijuana, there’s already a thriving black market for Psychedelics that speaks to their popularity. And attitudes are changing, thanks in part to Michael Pollan’s 2018 book on micro-dosing and a designation from the FDA the same year that fast-tracked a Psilocybin-based treatment for depression from Compass Pathways CMPS based on preliminary clinical evidence. Investors noticed. When Compass, backed by Facebook, Inc. FB and PayPal Holdings Inc PYPL investor Peter Thiel, went public this September, its shares jumped 71% in the first day of trading.

READ FULL PSYCHEDELICS INVESTMENT ARTICLE

Photo by Jeff W on Unsplash